Alvotech (ALVO) Long-Term Debt Repayments (2021 - 2026)
Alvotech (ALVO) posted Long-Term Debt Repayments of -$9.0 million for Q1 2026, down 216.89% on a QoQ basis from $7.7 million in Q3 2025, and down 153.89% year-over-year from $16.8 million in Q1 2025.
Alvotech (ALVO) Long-Term Debt Repayments (2021 - 2026) Analysis & Trends
Alvotech's Long-Term Debt Repayments history runs 6 years deep, the most recent figure standing at -$9.0 million for Q1 2026.
- Quarterly Long-Term Debt Repayments fell 153.89% year-over-year to -$9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.1 million (up 98.79% YoY) and the FY2023 annual result came in at -$99.4 million, down 1968.85% from the prior year.
- Long-Term Debt Repayments was -$9.0 million for Q1 2026 at Alvotech, down from $7.7 million in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $75.8 million in Q3 2024 and bottomed at -$749.1 million in Q4 2024.
- A 5-year average of -$81.3 million and a median of -$21.4 million in 2023 frame the typical range for Long-Term Debt Repayments.
- Peak annual rise in Long-Term Debt Repayments reached 96.79% in 2024, while the deepest fall reached 653.85% in 2024.
- Alvotech's Long-Term Debt Repayments stood at -$34.7 million in 2022, then plunged by 186.24% to -$99.4 million in 2023, then sank by 653.85% to -$749.1 million in 2024, then jumped by 101.03% to $7.7 million in 2025, then tumbled by 216.89% to -$9.0 million in 2026.
- Business Quant data shows ALVO's Long-Term Debt Repayments at -$9.0 million in Q1 2026, $7.7 million in Q3 2025, and -$4.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 23.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -478.39 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | -9.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.05 Mn |
| Mar 31, 2026 | -9.05 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Jun 30, 2025 | -4.19 Mn |
| Jun 30, 2025 | -4.19 Mn |
| Mar 31, 2025 | -3.56 Mn |
| Mar 31, 2025 | -3.56 Mn |
| Dec 31, 2024 | -749.08 Mn |
| Dec 31, 2024 | -749.08 Mn |
| Sep 30, 2024 | 75.80 Mn |
| Sep 30, 2024 | 75.80 Mn |
| Jun 30, 2024 | -73.43 Mn |
| Jun 30, 2024 | -73.43 Mn |
| Mar 31, 2024 | -1.63 Mn |
| Mar 31, 2024 | -1.63 Mn |
| Dec 31, 2023 | -99.37 Mn |
| Dec 31, 2023 | -99.37 Mn |
| Jun 30, 2023 | -33.70 Mn |
| Jun 30, 2023 | -33.70 Mn |